Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer

NCT03898791 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03898791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03898791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2019
Completion date
March 30, 2021
Enrollment
48 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer